+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Bispecific Antibodies Market by Mechanism of Action (Dual Antigen Targeting, Dual-Blocking Antibodies, T-cell Engagers), Therapeutic Area (Autoimmune Diseases, Infectious Diseases, Neurological Disorders), End-user - Forecast 2024-2030

  • PDF Icon

    Report

  • 186 Pages
  • June 2024
  • Region: Global
  • 360iResearch™
  • ID: 5968310
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Bispecific Antibodies Market grew from USD 4.36 billion in 2023 to USD 6.14 billion in 2024. It is expected to continue growing at a CAGR of 42.24%, reaching USD 51.47 billion by 2030.

This dual-targeting ability distinguishes them from traditional monoclonal antibodies developed to bind to a single antigen. The primary applications of bispecific antibodies reside in the therapeutic domain, particularly in targeting and neutralizing cancer cells. Their unique capability allows them to bring effector cells in close proximity to cancer cells, enhancing the immune system's ability to combat cancer. Additionally, their use in research to understand disease mechanisms further aligns with their application in creating more effective treatments for autoimmune and inflammatory diseases. Several factors contribute to the growth of the bispecific antibodies market, including rising incidences of cancer and other chronic illnesses globally, advancements in genetic engineering and protein engineering technologies, and growing regulatory support for innovative therapies for developing and approving novel bispecific antibodies. However, the expansion of bispecific antibodies is hindered by the high costs of the development of bispecific antibodies and the manufacturing complexities associated with bispecific antibodies. On the other hand, expanding usage of bispecific antibodies in the treatment of rare diseases and rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies opens new avenues for the bispecific antibodies market.

Regional Insights

The United States is at the forefront of the market demand and the development of bispecific antibodies, backed by robust R&D infrastructure, significant healthcare spending, and a strong patent portfolio. The FDA's supportive regulatory framework accelerates the approval of innovative therapies, encouraging substantial investments in biotechnology firms focused on BsAbs. Canada showcases a growing interest in bispecific antibody therapies, with research institutions and biotech startups receiving government and private funding. The South American market for bispecific antibodies is in a nascent stage; however, it exhibits potential for significant growth due to increasing healthcare expenditure, rising awareness about innovative cancer treatments, and improving healthcare infrastructure, contributing to the market expansion in this region. In the European Union, there's a strong emphasis on the adoption of advanced therapeutic solutions, including bispecific antibodies. The EMA's (European Medicines Agency) proactive approach to approving novel treatments and high healthcare expenditure and patient awareness fosters a favorable environment for BsAbs. The Middle East and Africa show a slower adoption of bispecific antibodies, primarily due to limited healthcare infrastructure and lower healthcare spending. However, certain countries in the Middle East, such as UAE and Saudi Arabia, are making strides in the healthcare sector, which could provide an impetus to the bispecific antibodies market. The APAC region is witnessing remarkable growth in the bispecific antibodies market, driven by escalating healthcare expenditure, rising cancer incidence, and growing awareness about advanced therapies. China and Japan are at the forefront, spearheading research and development in the bispecific antibodies. Regulatory reforms, expanding healthcare infrastructures, and partnerships between local biotech firms and international pharmaceutical giants are key factors propelling the market in APAC.

Market Insights

Market Dynamics

  • The market dynamics represent an ever-changing landscape of the Bispecific Antibodies Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

  • Rising incidences of cancer and other chronic illnesses globally
  • Advancements in genetic engineering and protein engineering technologies
  • Growing regulatory support for innovative therapies for the development and approval of novel bispecific antibodies

Market Restraints

  • High cost regarding the development of bispecific antibodies

Market Opportunities

  • Expanding usage of bispecific antibodies in the treatment of rare diseases
  • Rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies

Market Challenges

  • Manufacturing complexities associated with bispecific antibodies

Market Segmentation Analysis

  • Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
  • Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells

Industry Insights

  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Bispecific Antibodies Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Bispecific Antibodies Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

AstraZeneca aims for '2.0' cancer pipeline, shares bispecific data

AstraZeneca PLC announced the advance of its oncology inventory by revealing insights into three promising bispecific antibody candidates at the European Society for Medical Oncology (ESMO) Congress. The firm's enhanced 2.0 portfolio of engineered antibodies can attach to two distinct tumor antigens, offering a dual mechanism of action that could revolutionize cancer treatment when integrated with AstraZeneca's existing drug arsenal.

U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma

Janssen Pharmaceutical Companies of Johnson & Johnson acquired approval for its advanced bispecific antibody, TALVEY (talquetamab-tgvs), from the U.S. Food and Drug Administration (FDA). This approval marks a significant advancement for adult patients going through relapsed or refractory multiple myeloma who have undergone at least four previous lines of therapy.

Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance

Pfizer Inc. received significant advancements from regulatory authorities for elranatamab, an innovative investigational bispecific antibody to treat relapsed or refractory multiple myeloma (RRMM). This novel therapy leverages its dual targeting mechanism against BCMA and CD3 receptors on malignant and T-cells.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Bispecific Antibodies Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Bispecific Antibodies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adimab, LLC, Affimed GmbH, Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd., Genmab A/S, Gilead Sciences, Inc., Innovent Biologics, Janssen Global Services, LLC by Johnson & Johnson Pte. Ltd., MacroGenics, Inc., Merck KGaA, Mereo Biopharma Group PLC, Merus N.V., Novartis AG, Pfizer Inc., Pieris Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., TG Therapeutics, Inc., and Xencor, Inc..

Market Segmentation & Coverage

This research report categorizes the Bispecific Antibodies Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism of Action

  • Dual Antigen Targeting
  • Dual-Blocking Antibodies
  • T-cell Engagers

Therapeutic Area

  • Autoimmune Diseases
  • Infectious Diseases
  • Neurological Disorders
  • Oncology

End-user

  • Hospitals & Specialist Clinics
  • Research Institutions & Academic Centers

Region

Americas

  • Argentina
  • Brazil
  • Canada
  • Mexico
  • United States
  • California
  • Florida
  • Illinois
  • New York
  • Ohio
  • Pennsylvania
  • Texas

Asia-Pacific

  • Australia
  • China
  • India
  • Indonesia
  • Japan
  • Malaysia
  • Philippines
  • Singapore
  • South Korea
  • Taiwan
  • Thailand
  • Vietnam

Europe, Middle East & Africa

  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Purchase of this report includes 1 year online access with quarterly updates

Purchase of this report includes 1 year online access with quarterly updates

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidences of cancer and other chronic illnesses globally
5.1.1.2. Advancements in genetic engineering and protein engineering technologies
5.1.1.3. Growing regulatory support for innovative therapies for the development and approval of novel bispecific antibodies
5.1.2. Restraints
5.1.2.1. High cost regarding the development of bispecific antibodies
5.1.3. Opportunities
5.1.3.1. Expanding usage of bispecific antibodies in the treatment of rare diseases
5.1.3.2. Rising investments in healthcare infrastructure and research & development activities by pharmaceutical companies
5.1.4. Challenges
5.1.4.1. Manufacturing complexities associated with bispecific antibodies
5.2. Market Segmentation Analysis
5.2.1. Mechanism of Action: Increasing preference for dual antigen targeting for minimizing off-target effects
5.2.2. Therapeutic Area: Expanding application of bispecific antibodies in oncology for engaging and destroying cancer cells
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Bispecific Antibodies Market, by Mechanism of Action
6.1. Introduction
6.2. Dual Antigen Targeting
6.3. Dual-Blocking Antibodies
6.4. T-cell Engagers
7. Bispecific Antibodies Market, by Therapeutic Area
7.1. Introduction
7.2. Autoimmune Diseases
7.3. Infectious Diseases
7.4. Neurological Disorders
7.5. Oncology
8. Bispecific Antibodies Market, by End-user
8.1. Introduction
8.2. Hospitals & Specialist Clinics
8.3. Research Institutions & Academic Centers
9. Americas Bispecific Antibodies Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Bispecific Antibodies Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Bispecific Antibodies Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. AstraZeneca aims for '2.0' cancer pipeline, shares bispecific data
12.3.2. U.S. FDA Approves TALVEY™ (talquetamab-tgvs), a Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma
12.3.3. Pfizer’s Elranatamab Receives FDA and EMA Filing Acceptance
12.4. Strategy Analysis & Recommendation
13. Competitive Portfolio
13.1. Key Company Profiles
13.2. Key Product Portfolio
List of Figures
FIGURE 1. BISPECIFIC ANTIBODIES MARKET RESEARCH PROCESS
FIGURE 2. BISPECIFIC ANTIBODIES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BISPECIFIC ANTIBODIES MARKET DYNAMICS
FIGURE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
FIGURE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 22. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. BISPECIFIC ANTIBODIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL ANTIGEN TARGETING, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY DUAL-BLOCKING ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY T-CELL ENGAGERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY HOSPITALS & SPECIALIST CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL BISPECIFIC ANTIBODIES MARKET SIZE, BY RESEARCH INSTITUTIONS & ACADEMIC CENTERS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 32. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 33. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 34. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 35. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 36. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 37. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 38. AMERICAS BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 39. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 40. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 41. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 42. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 43. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 44. ARGENTINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 45. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 46. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 47. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 48. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 49. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 50. BRAZIL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 51. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 52. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 53. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 54. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 55. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 56. CANADA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 57. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 58. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 59. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 60. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 61. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 62. MEXICO BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 63. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 64. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 65. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 66. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 67. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 68. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 69. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 70. UNITED STATES BISPECIFIC ANTIBODIES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 72. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 74. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 76. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 77. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 78. ASIA-PACIFIC BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 79. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 80. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 81. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 82. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 83. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 84. AUSTRALIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 85. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 86. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 87. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 88. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 89. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 90. CHINA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 91. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 92. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 93. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 94. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 95. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 96. INDIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 97. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 98. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 99. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 100. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 101. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 102. INDONESIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 103. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 104. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 105. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 106. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 107. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. JAPAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 110. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 111. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 112. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 113. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 114. MALAYSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 115. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 116. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 117. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 118. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 119. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 120. PHILIPPINES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 121. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 122. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 123. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 124. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 125. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 126. SINGAPORE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 127. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 128. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 129. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 130. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 131. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 132. SOUTH KOREA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 133. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 134. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 135. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 136. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 137. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 138. TAIWAN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 139. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 140. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 141. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 142. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 143. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 144. THAILAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 145. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 146. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 147. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 148. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 149. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 150. VIETNAM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 159. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 160. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 161. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 162. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 163. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 164. DENMARK BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 165. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 166. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 167. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 168. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 169. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 170. EGYPT BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 171. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 172. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 173. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 174. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 175. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 176. FINLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 177. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 178. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 179. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 180. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 181. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 182. FRANCE BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 183. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 184. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 185. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 186. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 187. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 188. GERMANY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 189. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 190. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 191. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 192. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 193. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 194. ISRAEL BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 195. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 196. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 197. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 198. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 199. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 200. ITALY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 201. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 202. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 203. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 204. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 205. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 206. NETHERLANDS BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 207. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 208. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 209. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 210. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 211. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 212. NIGERIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 213. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 214. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 215. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 216. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 217. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 218. NORWAY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 219. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 220. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 221. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 222. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 223. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 224. POLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 225. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 226. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 227. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 228. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 229. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 230. QATAR BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 231. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 232. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 233. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 234. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 235. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 236. RUSSIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 238. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 240. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 241. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. SAUDI ARABIA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 244. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 246. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 248. SOUTH AFRICA BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 249. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 250. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 251. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 252. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 253. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 254. SPAIN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 255. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 256. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 257. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 258. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 259. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 260. SWEDEN BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 261. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 262. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 263. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 264. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 265. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 266. SWITZERLAND BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 267. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 268. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 269. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 270. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 271. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 272. TURKEY BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 276. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 277. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 278. UNITED ARAB EMIRATES BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2018-2023 (USD MILLION)
TABLE 280. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY MECHANISM OF ACTION, 2024-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2018-2023 (USD MILLION)
TABLE 282. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY THERAPEUTIC AREA, 2024-2030 (USD MILLION)
TABLE 283. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 284. UNITED KINGDOM BISPECIFIC ANTIBODIES MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 285. BISPECIFIC ANTIBODIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 286. BISPECIFIC ANTIBODIES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Adimab, LLC
  • Affimed GmbH
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Innovent Biologics
  • Janssen Global Services, LLC by Johnson & Johnson Pte. Ltd.
  • MacroGenics, Inc.
  • Merck KGaA
  • Mereo Biopharma Group PLC
  • Merus N.V.
  • Novartis AG
  • Pfizer Inc.
  • Pieris Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi S.A.
  • TG Therapeutics, Inc.
  • Xencor, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages186
PublishedJune 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.14 Billion
Forecasted Market Value ( USD ) by 2030 $ 51.47 Billion
Compound Annual Growth Rate42.2%
Regions CoveredGlobal

Related Topics

Related Reports

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029 - Product Image

Global Bispecific Antibody Market, Drugs Sales, Patent, Price & Clinical Trials Insight 2029

  • Report
  • 1200 Pages
  • Global
From
Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029 - Product Image

Global Multispecific Antibodies Market, Drug Sales, Price & Clinical Trials Insight 2029

  • Report
  • 1200 Pages
  • Global
From
Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 180 Pages
  • Global
From
Global Bispecific Antibody Therapeutics Contract Manufacturing Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Global Bispecific Antibody Therapeutics Contract Manufacturing Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From
Global Bispecific Antibodies for Cancer Market 2024-2028 - Product Image

Global Bispecific Antibodies for Cancer Market 2024-2028

  • Report
  • 172 Pages
  • Global
From

About the Bispecific Antibodies Market

Bispecific antibodies are a type of biotechnology that are used to target two different antigens simultaneously. They are engineered to bind to two different epitopes on the same or different antigens, allowing them to act as a bridge between two different cells or molecules. Bispecific antibodies have been used in a variety of therapeutic applications, including cancer immunotherapy, autoimmune diseases, and infectious diseases. Bispecific antibodies have the potential to improve the efficacy of existing treatments and to develop new treatments for diseases that have not yet been addressed. They can also be used to target multiple antigens at once, allowing for more efficient and effective treatments. The bispecific antibodies market is expected to grow significantly in the coming years due to the increasing demand for targeted therapies and the development of new technologies. Companies in the market include AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Genentech, GlaxoSmithKline, Merck, Novartis, and Pfizer. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.